Diagnostic impacts of DBT and ABVS for breast cancer screening in comparison with MMG and HUS

2427 women (mean age 60.0 years; range 20-94 years) were screened with DBT and ABVS from May 2014 to December 2018. 5375 women (mean age 57.3 years; range 40-84 years) were screened with MMG and HUS from February 2004 to December 2013. Number of recall cases (rate), unidentified cases, further exams, identified outcome cases, breast cancer cases, false positive cases, positive predictive value (PPV), cancer detection rate, implementation rate of further exams (fine needle aspiration (FNA), core needle biopsy (CNB), vacuum-assisted breast biopsy(VAB)) were evaluated between two groups. The recall rate was lower in women with DBT and ABVS in comparison with women with MMG and HUS (7.9 % vs 8.2%; p>0.05). Detection rate of breast cancers was higher in women with DBT and ABVS than women with MMG and HUS (1.6% vs 1.2%; p>0.05). Non-cancer rate among women receiving invasive procedures was lower in women with DBT and ABVS in comparison with women with MMG and HUS (0.9% vs 1.0%; p>0.05). PPV was significantly higher in women with DBT and ABVS in comparison with women with MMG and HUS (19.9% vs 14.5%; p=0.045). DBT and ABVS screening improved the cancer detection rate with significant higher PPV in comparison with MMG and HUS for breast cancer screening.